by direct action on dopamine binding sites (transporter or receptors) or indirectly by affecting other neurotransmitter systems that modulate the dopamine system. In principle, a medication could act via one of three mechanisms: (i) as a substitute for cocaine by producing similar dopamine effects; (ii) as a cocaine antagonist by blocking the binding of cocaine to the dopamine transporter; or (iii) as a modulator of cocaine effects by acting at other than the cocaine binding site.
The US National Institute on Drug Abuse has a Clinical Research Efficacy Screening Trial (CREST) programme to rapidly screen existing medications. CREST identified four medications warranting phase II controlled clinical trials: cabergoline, reserpine, sertraline and tiagabine. In addition, disulfiram and selegiline (deprenyl) have been effective and well tolerated in phase II trials. However, selegiline was found ineffective in a recent phase III trial.
Promising existing medications probably act via the first or third aforementioned mechanisms. Sustained-release formulations of stimulants such as methylphenidate and amfetamine (amphetamine) have shown promise in a stimulant substitution approach. Disulfiram and selegiline increase brain dopamine concentrations by inhibition of dopamine-catabolising enzymes (dopamine-β-hydroxylase and monoamine oxidase B, respectively). Cabergoline is a direct dopamine receptor agonist, while reserpine depletes presynaptic stores of dopamine (as well as norepinephrine and serotonin). Sertraline, baclofen and vigabatrin indirectly reduce dopamine activity by increasing activity of neurotransmitters (serotonin and GABA) that inhibit dopamine activity.
Promising new medications act via the second or third aforementioned mechanisms. Vanoxerine is a long-acting inhibitor of the dopamine transporter which blocks cocaine binding and reduces cocaine self-administration in animals. Two dopamine receptor ligands that reduce cocaine self-administration in animals are also undergoing phase I human safety trials. Adrogolide is a selective dopamine D 1 receptor agonist; BP 897 is a D3 receptor partial agonist.
A pharmacokinetic approach to treatment would block the entry of cocaine into the brain or enhance its catabolism so that less cocaine reached its site of action. This is being explored in animals using the natural cocaine-metabolising enzyme butyrylcholinesterase (or recombinant versions with enhanced capabilities), catalytic antibodies, and passive or active immunisation to produce anti-cocaine binding antibodies. A recent phase I trial of a 'cocaine vaccine' found it to be well tolerated and producing detectable levels of anti-cocaine antibodies for up to 9 months after immunisation.
Scope of the Problem
spread evenly around the world. Two-thirds (67.9%) of cocaine users live in the Americas (47% in North Cocaine use and misuse represent a significant America) and another fifth (20.9%) in Western Euglobal public health problem. The United Nations rope. In contrast, only 3% live in Asia and Oceania. Drug Control Program (UNDCP) estimates that coEspecially detailed information about the extent caine use affects about 13.4 million people (0.3% of of cocaine use and its consequences is available the global population above age 14 years), making it from the US. The National Household Survey on the second most common illegal drug of abuse in terms of treatment demand. [1] This problem is not Drug Abuse [2] estimated in 2001 that 27 788 000 Americans had used cocaine at least once in their ance coverage and price resistance by government funders. lifetime, 4 186 000 had used it in the past year, 1 676 000 had used it in the past month and 756 000
This article describes the potential leads to effective medication provided by the increasing knowwere dependent on cocaine (by US psychiatric criteledge of the neuropharmacology of cocaine, and ria [3] ). These estimates are based on interviews with then briefly reviews those medications currently a stratified random sample of 68 929 non-instituundergoing clinical evaluation. tionalised individuals 12 years or older designed to be representative of the US population. That same 2. Approaches to the Problem year a survey of over 500 acute care hospitals estimated that 193 034 cocaine-using patients visited hospital emergency departments in 2001, a rate of 2.1 Pharmacological Strategies 76 visits per 100 000 population.
[4] A 1999 survey of In principle, at least four pharmacological appublically funded substance abuse treatment proproaches might be useful in the treatment of cocaine grammes in the US found almost a quarter of a dependence. [6, 7] First, substitution treatment with a million (218 311) patients seeking treatment for cocross-tolerant stimulant might suppress withdrawal caine abuse. [5] In addition to the direct effects of symptoms and cocaine craving and/or make patients cocaine, cocaine use contributes to other health tolerant to acute reinforcing effects of cocaine. This problems, such as the spread of infectious diseases is analogous to methadone maintenance treatment (e.g. HIV, hepatitis C and tuberculosis).
for heroin dependence or nicotine replacement therThese epidemiological data illustrate the continu-apy for tobacco dependence. Compounds that mimic ing need for effective treatment for cocaine depend-the effects of cocaine should have a slow onset of ence. More than two dozen medications developed action (and slow binding to site of action) to miniand marketed for other indications have been evalu-mise substance abuse liability.
[10] Secondly, an anated as treatment for cocaine dependence (for re-tagonist medication that blocks the binding of coviews, see Gorelick [6, 7] and de Lima et al. [8] ). Yet, caine to its site of action might lead to extinction of after almost two decades of research, there is still no cocaine-taking behaviour because cocaine would no well established, effective medication for the treat-longer be rewarding. This is analogous to naltrexone ment of cocaine dependence, nor is any medication treatment for heroin dependence (naltrexone being a approved for this indication by any national medica-long-acting antagonist at the opioid μ receptor at tions regulatory authority (such as the US FDA). which heroin acts). Thirdly, a medication might act One factor contributing to this lack is the relatively at other sites to functionally antagonise the effects of small amount of drug development activity for this cocaine, leading to a reduction of reinforcing effects indication by pharmaceutical companies, especially of or craving for cocaine. Because cocaine is considlarge multinational companies. In addition to per-ered to exert its reinforcing effect primarily by inceived inadequacy of the science base, several mar-creasing dopamine activity in the brain mesocorket barriers have been identified as contributing to ticolimbic 'reward' circuit, this approach might be the dearth of activity by pharmaceutical compa-implemented by influencing brain dopamine acnies: [9] (i) the small and uncertain market for cocaine tivity, either by direct action on dopamine binding dependence pharmacotherapy, because of uncertain sites (see section 3.1) or by affecting other neuromarket penetration and poor patient compliance; (ii) transmitters that modulate dopamine activity (see a substance abuse treatment system that limits ac-section 3.2). [11, 12] This is analogous to naltrexone cess to the market because of limited physician treatment for alcoholism (alcohol does not act diinvolvement and anti-medication attitudes among rectly on the opioid μ receptors blocked by naltrexnon-physician clinicians; and (iii) limited and uncer-one, but its effects are influenced by endogenous tain payment for medication because of poor insur-opioid activity). Fourthly, cocaine pharmacokinetics could be altered so that less drug reached the brain taking. These are triggers that can provoke relapse to or remained at its site(s) of action in the brain (see drug taking in humans. section 6).
3. The conditioned place preference model uses Preclinical research has focused on several ap-Pavlovian conditioning to model drug craving (for proaches to these goals: (i) development of more review, see Tzschentke [16] ). Animals are tested selective ligands for the presynaptic dopamine (when free of drug) to determine whether they prefer transporter, the presumed major site of action for an environment in which they previously expericocaine in producing dependence, and for the sever-enced drug as compared with another environment. al subtypes of dopamine receptors; (ii) manipulation 4. The drug discrimination model assesses the deof other neurotransmitter systems that influence the gree to which the subjective effects of one drug dopaminergic reward system; (iii) prevention or resemble the subjective effects of another drug (for amelioration of consequences of actions of cocaine; review, see Colpaert [17] ). The animal is trained to and (iv) alteration of cocaine pharmacokinetics to make one response when drugged (e.g. with coreduce brain concentrations.
caine) and another when given inactive vehicle. It is used in anti-addiction drug development to evaluate
Animal Models
whether a putative therapeutic agent enhances or diminishes the overall subjective state induced by Preclinical animal models of cocaine dependence the addictive drug (e.g. cocaine). and relapse are used to screen for potential clinically 5. The electrical brain stimulation reward model effective anti-addiction medications. The true pre-assesses the degree of drug-induced enhancement of dictive validity of any animal model is unknown brain reward in animals trained to respond for elecuntil an effective treatment medication is available trical stimulation of specific brain-reward loci, such as a 'gold standard'.
as the ventral tegmental area, medial forebrain bunThe following six behavioural models are com-dle, and nucleus accumbens. [18] This model is useful monly used in preclinical research to develop new both to screen compounds for potential anti-addicmedications for the treatment of cocaine (and other tive therapeutic properties and, conversely, to screen drug) dependence. [13] compounds for potential reward-enhancing proper-1. Drug self-administration is the model with the ties, which might be predictive of addictive potenmost face validity for human drug taking. [14] Labora-tial. tory animals will work to self-administer addictive 6. The behavioural sensitisation (sometimes termed drugs such as cocaine by a variety of routes of reverse tolerance) model refers to the progressive administration. In a variant of this model, animals increase of behavioural responses to psychostimuwill work to receive a sensory stimulus previously lants that develops during their repeated administraassociated with drug administration (so-called tion, an effect that persists long after drug withdrawsecond-order reinforcement model). This has been al. [19, 20] Locomotor sensitisation in rodents has been considered an animal model of drug seeking.
used as an animal model of the progressive intensifi-2. The reinstatement model is considered a model of cation of drug-induced reward and/or incentive morelapse to drug use after abstinence (for review, see tivation, [21] the latter perhaps relating to drug cravShaham et al. [15] ). Animals are trained to stable drug ing and relapse. self-administration behaviour, and then the drugtaking behaviour is completely extinguished. Re-3. Drug Development Strategies lapse to drug-taking behaviour is then provoked by exposure to external stimuli. Three types of external A wide variety of compounds have been evalustimuli reliably trigger relapse in this model -a ated for therapeutic potential, based upon current single 'free' administration of drug, stress, or envi-knowledge (or belief) about the brain mechanisms, ronmental stimuli previously associated with drug loci and neurotransmitter systems underlying drug taking, drug seeking and/or relapse. A promising animals self-administering intravenous cocaine apcompound is considered one that reduces effects of pear to do so in order to maintain nucleus accumcocaine in animal models (e.g. self-administration, bens dopamine levels within a set range, with deconditioned place preference, reinstatement of drug creased nucleus accumbens dopamine triggering votaking) at doses that do not disrupt other behaviours. litional self-administrations and increased nucleus A promising compound should preferably not itself accumbens dopamine correlating with behavioural be self-administered, suggesting that it has low indices of receipt of drug reward. Therefore, much abuse liability.
preclinical research has been devoted to pharmacotherapeutic strategies targeted on this dopamine system.
Direct Action on the Dopamine System
The addictive qualities of cocaine are believed to
Compounds Targeting the Dopamine Transporter
be mediated primarily by its enhancement of activity in the meso-accumbens dopamine system of the Primate, including human, studies show a posibrain. This enhancement occurs by cocaine binding tive correlation between dopamine transporter occuto presynaptic dopamine transporters and blocking pancy by cocaine and the positive reinforcing effects the reuptake of dopamine, resulting in more dop-of cocaine, with at least 50% occupancy needed to amine remaining in the synapse (for review, see produce an effect. [23, 24] Reduction of cocaine selfGardner, [14] Wise and Gardner [22] ). Evidence that administration in animals by dopamine transporter this action mediates rewarding and reinforcing ef-blockers is also associated with their degree of transfects of cocaine includes the facts that: (i) brain-porter occupancy, with at least 50% occupancy restimulation reward is elicited specifically from quired to show an effect. [23] dopaminergic loci within the meso-accumbens dopThese findings suggest the potential of dopamine amine system; (ii) dopamine antagonists selectively transporter blockers [25] with slow onset and long inhibit brain-stimulation reward at doses that have duration of action to minimise abuse liability. no effect on motor performance; (iii) cocaine potenSelectivity in blocking the cocaine binding site withtiates the rewarding effects of brain-stimulation reout affecting the dopamine site (thereby leaving ward; (iv) the potencies of cocaine and cocaine-like normal dopamine reuptake) is also desirable in drugs in animal self-administration studies correlate minimising abuse liability. [26] A wide variety of highly with their potencies to bind to the dopamine chemical structures have been used as templates in transporter but not to other presynaptic and postdeveloping such a compound. These include cosynaptic binding sites; (v) cocaine is preferentially caine analogues, [27] methylphenidate analogues, [26] self-administered by animals into dopaminergic tropanes, [28] benzatropine (benztropine) anabrain loci as opposed to other brain loci; (vi) doplogues, [29] substituted piperazines [30] and inamine-selective lesions of the nucleus accumbens danamines. [31] attenuate the rewarding effects of intravenous coDrugs that rapidly enter the brain and quickly caine; (vii) dopaminergically selective pharmacoelevate nucleus accumbens dopamine levels appear logical blockade enhances intravenous cocaine selfto have high addictive potential.
[32] Thus, the best administration at low doses (a compensatory effect, candidates are compounds with slow onset and/or similar to the effect of decreasing the amount of prolonged duration of action, which appear to confer cocaine per infusion) and completely blocks it at lower addictive potential. Table I lists promising higher doses; (viii) addictive drugs, including cocompounds in this class and their effects in various caine, preferentially increase dopamine levels in the animal models. One compound from this class, nucleus accumbens as opposed to other brain loci; vanoxerine (GBR 12909), is currently undergoing (ix) self-administered cocaine preferentially eleclinical evaluation (see section 5). vates nucleus accumbens dopamine levels; and (x) 
Compounds Targeting Dopamine
dependence (for reviews, see Gardner [57] and
Receptor Subtypes
Volkow et al. [58] ). Another drug development strategy has been to D2 receptor ligands are no longer considered focus on the dopamine receptor itself, of which there promising candidates for drug development, despite are five currently known subtypes. [54] Attention in the role of D2 receptor-mediated mechanisms in anti-addiction drug development has focused chiefly brain reward, cocaine self-administration and coon the dopamine D1 and D3 receptor subtypes (see caine-induced conditioned place preference (for retable I). D1 receptor-mediated mechanisms are imview see Platt et al., [12] Rothman and Glowa [25] ). D2 plicated in the substrates of brain-stimulation rereceptor agonists are self-administered by animals ward, cocaine self-administration, cocaine-induced conditioned place preference, and cocaine-induced and enhance the behavioural effects of cocaine. D2 neurochemical and behavioural sensitisation (for re-receptor antagonists (e.g. antipsychotics used to view, see Platt et al. [12] and Rothman and Glowa [25] ). treat psychosis) do not stop cocaine use in humans, The D3 receptor, which is preferentially localised in even when taken in high doses, [59] [60] [61] [62] and often cause the mesolimbic dopamine system, [55] plays a role in clinically significant adverse effects such as dysphoemotional, motivational and reinforcement func-ria and abnormal movements. tions, including the reinforcement produced by ad- Table I lists dopaminergic compounds that have dictive drugs. [51] D3 receptor inhibition may activate been studied preclinically. Three such compounds the meso-accumbens dopamine system, [56] which are undergoing clinical evaluation (see section 5): has been postulated to be pathologically under-ac-CEE 03310 (D1 receptor antagonist), adrogolide tive in drug addicts and individuals vulnerable to (ABT 431; DAS 431) [D1 receptor agonist] and gic brain substrates relating to drug-induced reward BP 897 (D3 partial agonist). and relapse. [68] Table II The endogenous opioid peptides regulate and ward, associative learning related to dependence and modulate dopaminergic function within the doprelapse to drug-seeking behaviour. [63] [64] [65] These in-amine brain reward system and its forebrain projecclude serotonergic, endogenous opioid peptidergic, tions. [81, 82] Endogenous opioid neurons are found in GABAergic, glutamatergic, endocannabinoid and the ventral tegmental area, nucleus accumbens and neuropeptide (especially cholecystokinin [CCK] , ventral pallidum, and may play a role in neural neurotensin [NT] and corticotropin-releasing factor mechanisms mediating drug craving in the absence [CRF]) systems. A promising drug development of reward. [83] strategy is to indirectly modulate the dopamine cirEndogenous brain opioids belong to four distinct cuits relevant to dependence by targeting these other neurotransmitter families: the endorphins, enneurotransmitter systems.
kephalins, dynorphins and endomorphins.
[84-86]
Compounds Targeting the Serotonin System
These endogenous opioid peptide neurotransmitters Cocaine inhibits the presynaptic reuptake of sero-interact with three major classes of opioid receptors, tonin and has a high affinity for the serotonin 5-HT3 i.e. μ, δ and κ. Endomorphins display extremely receptor. [66, 67] The meso-accumbens dopamine re-high affinity and selectivity for the opioid μ recepward system is heavily innervated by serotonin af-tor, enkephalins for the opioid δ receptor, and dyferents from the raphe nuclei both at the level of the norphins for the opioid κ receptor. β-Endorphin ventral tegmental area and the nucleus accumbens. binds with about equal affinity to both opioid μ-and Serotonin also regulates and modulates dopaminer-δ receptors. Activation of opioid μ-and δ receptors gic function within the dopamine forebrain projec-enhances dopamine release in the nucleus accumtion systems. Thus, the serotonin system presents a bens and activates reward-related processes, wherepossible target for indirectly modulating dopaminer-as activation of opioid κ receptors inhibits dopamine release and produces aversion.
[82,85] Candidate com-focused on two approaches for increasing GABApounds which differentially target opioid μ-, δ-and ergic activity: (i) by inhibiting GABA transaminase, κ receptors have been evaluated preclinically for the primary enzyme involved in catabolism of possible utility as anti-cocaine medications.
GABA; or (ii) by directly stimulating GABA receptors with an agonist. [98, 99] receptor agonist, are the only compounds evaluated in humans. Several clinical trials suggest that highGlutamate is an amino acid neurotransmitter that dose buprenorphine reduces cocaine use (along with mediates most excitatory synaptic transmission in opioid use) in patients abusing both cocaine and the mammalian brain. Glutamatergic regulation of opioids.
the meso-accumbens dopamine reward-related circuitry involves extensive inputs into the ventral tegmental area and the nucleus accumbens. [114, 115] In
Compounds Targeting the GABAergic System
addition, there are glutamatergic interconnections within the meso-accumbens dopamine system. This GABA acts as an inhibitory neurotransmitter.
complex interconnected glutamatergic-dopaminerGABAergic neurons modulate meso-accumbens gic network (which also has GABAergic links) has brain reward functions via their heavy innervation been proposed to constitute a 'motive circuit' which within the ventral tegmental area and nucleus actranslates cortical information into adaptive behavcumbens. [96] Activation of GABAB receptors on ioural responses. [116] Functional dysregulation of dopamine perikarya inhibits meso-accumbens dopathis circuit has been proposed as a neural substrate minergic reward functions. [97] These findings have of drug dependence. [20, 114, 115] spurred the development of GABA-mimetic compounds acting specifically at the GABAB receptor as Glutamate receptors are divided into two famipossible anti-cocaine medications. Much work has lies: the ionotropic and the metabotropic. The iono-tropic glutamate receptor family is further divided Such preclinical findings suggest a number of potential pharmacotherapeutic targets. Normalisainto three types: NMDA, α-amino-3-hydroxy-5-tion (increase) in basal glutamate neurotransmission methyl-4-isoxasoleproprionate (AMPA) and kainate during cocaine withdrawal and abstinence might be receptors. The metabotropic glutamate receptor helpful in relieving drug craving and relapse, [117] family is also divided into three types, each with while a treatment that inhibits glutamate transmissubtypes: metabotropic glutamate group I receptors sion after re-exposure to cocaine might attenuate (containing the mGluR1 and mGluR5 receptor subrewarding effects of cocaine and abort the initiation types), metabotropic glutamate group II receptors of a cocaine binge. [118, 121] (containing the mGluR2 and mGluR3 receptor sub- Table V lists preclinical findings with glutatypes) and metabotropic glutamate group III recepmatergic compounds. Two NMDA receptor antagotors (containing the mGluR4, mGluR6, mGluR7 and nists are undergoing clinical evaluation (see section mGluR8 receptor subtypes).
4.5). Glutamate is a focus of anti-cocaine medication
Compounds Targeting the development because neuroadaptations within the

Endocannabinoid System
glutamate system may underlie some aspects of the Another brain neurotransmitter system that syndevelopment of cocaine dependence or the incubaaptically connects with and modulates the mesotion of relapse vulnerability. In general, acute coaccumbens dopaminergic reward-related system is caine administration has little effect on glutamate the endocannabinoid system. [136, 137] This system neurotransmission. On the other hand, repeated cocomprises several endogenous neurotransmitters/ caine administration results in neuroadaptations in neuromodulators, such as anandamide, which act on glutamate neurotransmission in both the ventral teg-cannabinoid CB1 receptors in the brain. Dronabinol mental area and nucleus accumbens. [114] [115] [116] Among (Δ-tetrahydrocannabinol), the psychoactive constitthese glutamatergic neuroadaptations is an enduring uent of marijuana, activates cannabinoid CB1 recepreduction in basal levels of nucleus accumbens tors, which results in activation of the meso-accumglutamate during cocaine withdrawal and markedly bens dopamine system. [138] A high-potency synthetenhanced glutamatergic transmission after re-expo-ic cannabinoid agonist, HU 210, triggers relapse to sure to cocaine. [117] [118] [119] [120] [121] The increased responsiveness cocaine-seeking behaviour in rats withdrawn from of the cocaine-withdrawn glutamate system to co-cocaine self-administration behaviour. [139] The caine re-exposure manifests itself only in the pres-cannabinoid CB1 receptor antagonist rimonabant ence of environmental cues that have been previous-(SR 141716A) blocks relapse to cocaine-seeking ly associated with cocaine, [122] suggesting that it behaviour in the reinstatement model that is trigmay constitute a neurobiological substrate of cue-gered by re-exposure to cocaine or to cocaine-assotriggered relapse.
ciated environmental cues, but not relapse triggered by stress. [139] These findings suggest an important and generally decreases dopamine-mediated behavrole for the endocannabinoid system in the neural iours. [142, 143] processes mediating relapse to cocaine-seeking be-
The endogenous CCK system modulates both the haviour and suggest that cannabinoid receptor ant-development and expression of cocaine sensitisaagonists are potentially useful anti-cocaine medica-tion.
[143,144] CCK1, but not CCK2, receptor-mediated tions in humans. However, no cannabinoid com-mechanisms in the nucleus accumbens play a key pound is currently undergoing clinical evaluation role in the acquisition, but not expression, of for the treatment of cocaine abuse.
cocaine-conditioned behaviour.
[142] Table VI lists preclinical findings with CCK agents.
Compounds Targeting Neuropeptides
Neurotensin
Several non-opioid neuropeptide neurotransmitter systems are potential targets for anti-cocaine There are three NT receptor types in the mammaaddiction pharmacotherapeutic agents, including lian brain: NT1, NT2 and NT3. [154] Their functions CCK, NT, CRF and neurotrophic factors.
remain poorly understood. The only known NT agonists are modified subfragments of the NT peptide Cholecystokinin itself. [155] Several non-peptide NT antagonists have been identified, of which reminertant (SR 48692) CCK is the most widespread and abundant and SR 142948A are the best characterised. [156, 157] neuropeptide in the mammalian CNS. [140, 141] Two CCK receptors have been identified: CCK1 (preSubstantial anatomical and functional interacviously known as CCK-A) and CCK2 (previously tions exist between the NT system and the mesoknown as CCK-B). CCK appears to be co-localised accumbens reward-related dopamine system. [158] with dopamine within the meso-accumbens reward-NT cell bodies, which co-localise dopamine and related circuit and to modulate nucleus accumbens CCK, are found preferentially in the ventral tegdopamine release. CCK1 receptor agonists excite mental area. They heavily innervate the basolateral dopaminergic neuronal firing, enhance nucleus ac-amygdala and the bed nucleus of the stria terminalis cumbens dopamine release and enhance dopamine--areas implicated in cue-triggered relapse and mediated behaviours. Activation of the CCK2 recep-stress-triggered relapse to cocaine-seeking behator decreases nucleus accumbens dopamine release viour, respectively. Most dopamine neurons in the ventral tegmental area express NT receptors, prima-istration, while inhibition of corticosterone derily the NT1 receptor. NT neurons in the nucleus creases cocaine self-administration. [163] Acute accumbens co-localise GABA and express D1, D2 cocaine withdrawal increases CRF release from the and D3 receptors. NT appears to act as a modulator central nucleus of the amygdala, [164] and decreases of dopaminergic function, rather than changing cell CRF-like immunoreactivity in the hypothalamus, firing on its own. NT/dopamine co-release appears amygdala and ventral limbic forebrain. [165] to serve as a limiting factor on dopaminergic transOn the basis of these findings, anti-CRF commission.
pounds have been studied as potential anti-cocaine methasone (suppression of ACTH [adrenocortico-CRF, or corticotropin-releasing hormone (CRH), trophic hormone] release) has not been effective in is another neuropeptide that functions as a neuro-phase I clinical trials (see section 4.8). However, transmitter and/or neuromodulator in the mammali-development of CRF antagonists remains an active an brain. [159] There are six CRF receptors, divided area. One caution in developing CRF1-receptor antinto three families: CRF1, CRF2 and CRF binding agonists as anti-cocaine medications is the potential protein (CRF-BP). The anatomical distribution of for abuse liability. At least one non-peptide CRF1-CRF-containing neurons and of CRF receptors sug-receptor antagonist, antalarmin (a close analogue of gests a role in the neural encoding of emotion and CP 154526), supports at least transient self-adminisstress, [160] and in mediating the hormonal and behav-tration by monkeys. [166] ioural manifestations of stress. [161] Brain Trophic Factors
In animal models, stress plays an important role in cocaine-seeking and cocaine-taking behaviour Neurotrophins, or neurotrophic factors, are tarand cocaine withdrawal. Stress increases self-ad-get-derived trophic factors which are crucial to the ministration of addictive drugs, potentiates their re-growth, differentiation, survival and maintenance of warding effects in the conditioned place preference neurons in the central and peripheral nervous sysmodel, triggers relapse to drug-seeking behaviour in tems. [167] One member of this family is brain-dethe reinstatement model and reinstates extinguished rived neurotrophic factor (BDNF). In addition to its electrical brain-stimulation reward. [159, 162] Adminis-purely trophic functions, BDNF appears also to tration of the stress hormone corticosterone facili-function as a neurotransmitter or neuromodulator in tates the acquisition of psychostimulant self-admin-the mammalian CNS. [168] Chronic microinfusion of BDNF into the nucleus accumbens or ventral teg-ject receiving standardised weekly psychosocial mental area enhances the initial stimulant effects of therapy. Outcome measures include urine bencocaine, facilitates the development of cocaine sen-zoylecgonine concentration (benzoylecgonine being sitisation and augments responding for a condi-the primary urinary metabolite of cocaine), selftioned reward. [169] Conversely, cocaine sensitisation reported cocaine use and structured observer ratings. is significantly attenuated in heterozygous BDNF
The CREST programme has tested 21 medicagene-deleted ('knock-out') mice. [169] tions to date (table VII) . Of these, four showed These findings suggest a role for meso-accum-enough promise to undergo further clinical efficacy bens dopamine system-associated BDNF in long-(phase II) trials: cabergoline, reserpine, sertraline term adaptations of the brain to cocaine. BDNF and tiagabine. Several other marketed medications protein levels in the mesolimbic reward-related dop-are being evaluated outside of the CREST proamine system show progressive augmentation over gramme (table VIII) , supported either by NIDA and/ a 90-day period following withdrawal from cocaine or pharmaceutical companies. self-administration [170] which precisely parallels the progressive incubation of vulnerability to cue-trig-
Dopaminergic Agents
gered relapse to cocaine-seeking behaviour over a similar 90-day period. [171] The implication is that Two dopaminergic agents, disulfiram and selegitime-dependent increases in BDNF levels may lead line (deprenyl), identified as promising by CREST to synaptic changes that mediate progressively enprogramme are undergoing more extensive, mulhanced vulnerability to relapse following the termitisite, clinical efficacy (phase III) trials. nation of cocaine self-administration. Thus, BDNF antagonists specific to the mesolimbic dopamine system are promising candidates for anti-cocainerelapse medication. There has been no clinical evaluation of BDNF-related compounds.
Marketed Medications Undergoing Clinical Evaluation
US National Institute on Drug Abuse Clinical Research Efficacy Screening Trial Programme
The US National Institute on Drug Abuse (NIDA) has an active medication development effort for treatment of cocaine abuse. One component of this effort is the Clinical Research Efficacy Screening Trial (CREST) programme. The goal of CREST is to rapidly and efficiently screen marketed medications to identify those with potential efficacy and safety that warrant further (and more expensive) evaluation. This is accomplished by single-blind testing of two to three medications and placebo at a time in parallel groups of 15-20 patients each. Each trial lasts 14 weeks (2 weeks baseline, 8 weeks medication and 4 weeks follow-up), with each sub- Disulfiram has been widely used for several de-should a patient not remain completely abstinent. A cades in the treatment of alcoholism. Several studies recent human laboratory study found that 3 days of found that at the commonly used dosage of pretreatment with disulfiram 250 mg/day signifidisulfiram 250 mg/day, it significantly reduced both cantly increased cocaine plasma concentrations and cocaine and alcohol use in outpatients dependent on potentiated the tachycardic and hypertensive effects both substances. [172, 173] The reduction in cocaine use of intranasal cocaine (1 or 2 mg/kg).
[178] Concern might have been secondary to the reduction in alco-over the safety of the triple interaction among hol use, because alcohol is known to trigger cocaine disulfiram, cocaine and alcohol has delayed initiacraving and use.
[174] However, three recent control-tion of a phase III clinical trial to confirm the effiled clinical trials found that disulfiram 250 mg/day cacy of disulfiram. A phase I clinical trial evaluating significantly reduced cocaine use even among co-the safety of these interactions is being conducted caine-dependent outpatients not also dependent on (A. Elkashef, personal communication). alcohol (but with concomitant opioid dependence in Selegiline, marketed for the treatment of Parkintwo studies). [175] [176] [177] One additional unpublished trial son's disease, is an irreversible inhibitor of monoalso found disulfiram to be better than placebo in amine oxidase (MAO). At the recommended dose of reducing cocaine use [table IX; F. Vocci, personal 10 mg/day, it is selective for MAO-B, the predomicommunication].
nant MAO type in brain, and does not substantially A possible mechanism for beneficial effect of inhibit MAO-A, the predominant type in the gastrodisulfiram is increased brain levels of dopamine intestinal tract. It is inhibition of MAO-A that leads (and/or decreased levels of norepinephrine). This to serious adverse interactions (e.g. hypertensive would be caused by inhibition of the enzyme dop-crisis) with tyramine-containing foods or catechoamine-β-hydroxylase, which catalyses the conver-laminergic medications. Phase I studies show that sion of dopamine to norepinephrine. One caution to selegiline is well tolerated by cocaine users and may the use of disulfiram is the possibility of adverse blunt the positive psychological effects of acute interactions among disulfiram, cocaine and alcohol, cocaine administration. [179] Selegiline, administered Weighted average of four studies (323) 51 38 CBT = cognitive-behavioural therapy; n = number of subjects.
as a transdermal patch to decrease the risk of inter-study as an antidepressant. [183] COMT is a major action with foods or medication, was recently evalu-extraneuronal inactivator of catecholamine neuroated in a phase III, multicentre, controlled clinical transmitters such as dopamine and norepinephrine. trial involving 300 cocaine-dependent outpa-Thus, tolcapone would be expected to increase doptients.
[180] Patients received either selegiline 20mg amine levels and activity in the brain. Clinical use of applied every 24 hours or a matching placebo for 8 tolcapone has been suspended in Europe because of weeks. Preliminary analysis of the data suggested no cases of acute liver failure. A clinical trial of tolsignificant benefit of selegiline over placebo.
capone-cocaine interactions in the US has been suspended because of concern over liver toxicity (J. The mechanism by which selegiline might exert a Mojsiak, personal communication). beneficial effect is not known. MAO-B catalyses the breakdown of catecholamines, such as dopamine
GABAergic Agents
and norepinephrine, so that its inhibition by selegiline would increase brain catecholamine levels.
Medications that increase brain GABA activity Selegiline has a neurotrophic effect by stimulating are attracting interest because GABA is an inhibitosynthesis of nerve growth factors, and may be ry neurotransmitter the activity of which inhibits neuroprotective as a scavenger of free radicals and dopamine release and reduces the reinforcing effects inhibitor of NMDA-mediated excitotoxicity. Final-of cocaine in animals [98, 184] (see section 3.2.3). ly, selegiline metabolites include amfetamine and Baclofen is a GABAB receptor agonist marketed as metamfetamine, which may act as substitutes for a muscle relaxant. Baclofen 20mg twice daily recocaine.
duced cocaine craving and use in a small open-label trial.
[185] In a human laboratory study with experiThree other marketed dopaminergic agents are enced cocaine users, baclofen 10-20mg twice daily undergoing phase II clinical trials. Cabergoline is a for 7-10 days reduced video cocaine cue-induced long-acting D2 receptor agonist marketed for the cocaine craving and cue-induced activation of antetreatment of hyperprolactinaemia. It is currently berior cingulate and amygdala brain regions (assessed ing evaluated in a multicentre, controlled clinical by positron emission tomography scanning). [98] A trial at a dosage of 0.5mg twice weekly for 12 recent phase II controlled clinical trial found that weeks. [181] Reserpine is a Rauwolfia alkaloid marbaclofen 20mg twice daily significantly reduced keted as an antihypertensive. It acts by depleting cocaine craving and increased the proportion of biogenic amines (including dopamine, norepinecocaine-abstinent subjects, although other outcome phrine and serotonin) in presynaptic and other tissue measures (e.g. proportion of cocaine-negative urine storage vesicles. A recent controlled clinical trial samples) showed no significant difference from plawas halted early because of failure to show efficebo.
[186] cacy. [181] Tolcapone is a reversible inhibitor of the enzyme catechol-O-methyl-transferase (COMT)
Tiagabine is marketed as an adjunctive which readily crosses the blood-brain barrier. [182] It antiepileptic drug. It acts as an inhibitor of presynapis marketed for Parkinson's disease [182] and under tic reuptake of GABA to increase functional GABA activity in synapses. Two recent 10-week, placebo-significantly better than placebo in reducing cocaine controlled clinical trials in methadone-stabilised co-use. [188, 196] caine users found that high-dose tiagabine (24 mg/ 4.4 Serotonergic Agents day), but not low dose (12 mg/day), significantly increased the proportion of cocaine-free urine samOndansetron is a selective 5-HT3 receptor antples compared with placebo. [187, 188] agonist marketed as an antiemetic. It is also being Valproate semisodium enhances brain GABA ac-evaluated in a phase II controlled clinical trial. Sertivity by one of several mechanisms, including in-traline is a selective serotonin reuptake inhibitor creased synthesis, decreased metabolism and/or marketed as an antidepressant and anxiolytic agent. potentiation of postsynaptic effects of GABA. It is A recent controlled clinical trial in depressed, marketed as an antiepileptic drug and mood stabilis-cocaine-dependent outpatients found sertraline er in mania. While earlier clinical trials were not 200 mg/day no better than placebo in relieving depromising, [189, 190] two more recent studies using pressive symptoms or reducing cocaine use. [197] higher doses (20 mg/kg/day) or achieved plasma concentrations (>50 mg/L) have reported better suc-4.5 NMDA Antagonists cess. [191, 192] Activation of the NMDA type of glutamate (exciTopiramate has a dual mechanism, both enhanctatory amino acid) receptor enhances activity in the ing GABA activity (by potentiating its effect on brain dopamine reward system, while their blockade chloride ion channels) and acting as a glutamate reduces such activity (see section 3.2.4) and reduces receptor antagonist. It is marketed as an antiepileptic cocaine-self-administration. [198] Clinical research on drug. A recent controlled clinical trial found that this treatment approach has been limited by the outpatients taking topiramate 200 mg/day had sigunavailability, until recently, of NMDA antagonists nificantly more cocaine-free urine samples than that could be used in humans. Memantine is a nonthose taking placebo, although both groups had fewcompetitive, low-to-moderate affinity NMDA anter such samples than at baseline. [193] agonist approved in the US for the treatment of Vigabatrin is a selective, irreversible inhibitor of Alzheimer's disease and in the EU for the treatment GABA transaminase, a main enzyme metabolising of various neurological disorders. [199] It is currently GABA. It is marketed outside the US as an anundergoing a placebo-controlled outpatient clinical tiepileptic drug, but is not approved in the US betrial (phase IIb), although an earlier phase IIa study cause of concern over visual field defects. A recent found that memantine 20 mg/day enhanced, rather open-label outpatient study in Mexico found that 8 than reduced, the psychological effects of coof 20 subjects achieved sustained cocaine absticaine. [200] nence of at least 4 weeks at a dosage of 2g twice daily. [194] Three other subjects reduced their cocaine
Calcium Channel Antagonists
use by at least 50%, while eight subjects dropped out within the first 10 days. Phase I and IIa controlled Calcium channel antagonists have been studied clinical trials in cocaine users are being planned.
as treatment for cocaine dependence because of their Gabapentin enhances GABA activity. It is mar-action in reducing cocaine-induced neurotransmitter keted as an antiepileptic drug, and also widely used release and reinforced behaviours in animal studies, as a mood stabiliser. An open-label outpatient trial and in preventing or reversing cocaine-induced defifound that gabapentin 800-2400 mg/day reduced cits in cerebral blood flow in humans. [201, 202] Prethe number of cocaine-positive urine samples and vious open-label outpatient case series found that increased the number of weeks of cocaine absti-several calcium channel antagonists (amlodipine, nence. [195] However, two recent controlled clinical diltiazem, nifedipine) did not reduce cocaine trials did not find gabapentin 1600 or 2400 mg/day use. [189, 203] Much current research attention has focused on in non-cocaine stimulant abusers. [217, 218] A recent isradipine, a dihydropyridine-type (L-type) calcium open-label trial in 13 cocaine-dependent outpatients channel antagonist marketed for hypertension. A found that modafinil 200 or 400 mg/day for 8 weeks recent interaction study found that subacute pre-was well tolerated and significantly improved treattreatment with isradipine (30 mg/day sustained re-ment retention and reduced cocaine use when comlease for 4 days, followed by 15 mg/day immediate pared with 23 placebo-treated subjects in another release for 3 days) reduced the acute psychological study. [212, 219] A phase II controlled clinical trial and blood pressure effects of a cocaine chal-found that modafinil 400 mg/day significantly inlenge. [204, 205] A placebo-controlled clinical trial of creased the cocaine abstinence rate compared with isradipine 2.5-5mg twice daily for 7 weeks found no placebo. [220] significant reduction in cocaine use, [206] suggesting that higher daily doses are needed for efficacy.
Other Medications
Buprenorphine is a partial opioid μ receptor ago-
Stimulants
nist and opioid κ receptor antagonist (see section Several research groups are working on a stimu-3.2.2) that is marketed worldwide as an analgesic lant substitution approach. Earlier studies using and for treatment of opioid dependence (both uses standard formulations of marketed stimulants such relying chiefly on its action at the opioid μ receptor). as amfetamine, methylphenidate and phenmetrazine Because of its addiction potential as an opioid μ gave disappointing results, with patients sometimes receptor agonist, buprenorphine has been studied reporting increased cocaine craving.
[7] Recent con-clinically only in cocaine-abusing patients with trolled clinical trials with amfetamine have been opioid dependence. Clinical studies suggest that more encouraging, especially those using sustained-sublingual buprenorphine, at high doses of release formulations. [207] [208] [209] Cocaine itself has been 8-16 mg/day, reduces cocaine use, as well as opioid used in phase IIa clinical trials. Chronic exposure to use, in patients abusing or dependent on both. [221, 222] either oral cocaine (100mg four times daily for 10
Citicoline is marketed in Europe and Japan as a days) or continuous 24-hour intravenous infusion treatment for ischaemic stroke and head trauma. [223] (0.25-0.5 mg/kg/h, total dose 6 mg/kg) has been Development of citicoline for the treatment of stroke well tolerated and reported to reduce the acute ef-has been halted in North America after disapfects of an intravenous cocaine challenge. [210, 211] pointing results in a recent 12-week phase III clinModafinil is a stimulant-like medication market-ical trial. [224] Citicoline is a naturally occurring ed for the treatment of excessive sleepiness. Al-mononucleotide that serves as an intermediary in the though its mechanism of action is not clearly under-biosynthesis of membrane phospholipids such as stood, it does inhibit the dopamine transporter and phosphatidylcholine. Administration enhances the enhance glutamate function. [212] Modafinil is self-incorporation of phospholipids into membranes and administered by animals and partially discriminated activates biosynthesis of structural phospholipids in as stimulant-like. In humans, it produces some stim-nerve cell membranes, potentially stimulating repair ulant-like psychological effects which are distin-of cocaine-damaged nerve cell membranes. Acute guishable from those of cocaine [213] and appears to treatment increases brain levels of dopamine and have less abuse liability. [214] Two recent double-norepinephrine. Citicoline is transformed in the blind interaction studies found that pretreatment CNS into uridine, a ligand at GABA receptors. It is with modafinil 200, 400 or 800 mg/day for 4 or 7 not known which of these effects might mediate a days blunted some of the acute psychological effects therapeutic response in cocaine dependence. [225] A of a cocaine challenge without causing any adverse phase I clinical trial found no harmful interactions cardiovascular effects. [215, 216] Several case reports between citicoline 1 g/day for 4 days and intranasal suggest that modafinil reduces craving and drug use cocaine 0.9 mg/kg, and no significant influence of citicoline pretreatment on the acute psychological or the animal and human studies. The most promising physiological effects of the cocaine challenge. [226] A results with HPA axis inhibition in rodent studies recent double-blind, placebo-controlled pilot study have been found during initial acquisition of cocaine involving 14 cocaine-dependent outpatients found self-administration or when low unit doses of selfthat citicoline 500mg twice daily for 8 weeks was administered cocaine are used, [232] that is, when the well tolerated, improved mood and sleep, and re-incentive and reward values of cocaine are low. This duced cocaine craving and use. [225] is not the case in human cocaine dependence. Also, the most promising animal findings with CRF antMetyrapone is marketed as a diagnostic agent for agonists were targeted at the central brain CRF hypothalamic-pituitary function. It blocks synthesis neural circuit originating in the central nucleus of of cortisol in the adrenal cortex by inhibiting the the amygdala and terminating in the bed nucleus of 11-β-hydroxylation reaction. Interest in metyrapone the stria terminalis, not the HPA axis (see section as a treatment for cocaine dependence stems from 3.2.6). Further research with CRF antagonists in preclinical studies suggesting that blockade of HPA human will be needed to clarify this situation. axis function, for example, with CRF antagonists, reduces the rewarding effects of cocaine (see section 3.2.6), and clinical observations on the associations 5. Unmarketed Medications Undergoing among stress, HPA hormones and cocaine dependClinical Evaluation ence.
[227] A recent human study found a significant association between intravenous cocaine-induced Animal studies have identified several comincreases in plasma ACTH concentrations and co-
pounds not yet marketed for any other clinical indicaine-induced euphoria, [228] suggesting a role for cation that show promise for the treatment of co-HPA hormones in the psychological effects of cocaine dependence, based on the neuropharmacologicaine. Two earlier phase I trials found no effect of cal mechanisms described in section 3. Several of attenuation of HPA axis function on the acute subthese have undergone phase I safety evaluation jective effects of smoked cocaine, either through (table X) . blockade of corticol synthesis by ketoconazole [229] Vanoxerine is a long-acting, noncompetitive inor suppression of pituitary function by dexamethhibitor of the presynaptic dopamine transporter asone.
[230] Despite these negative findings, a phase I which was originally developed as an antidepresstudy evaluating the interaction of metyrapone and sant. [233] In animal studies, self-administered vanoxintravenous cocaine is currently underway.
erine increases extracellular dopamine levels in the Prasterone (dehydroepiandrosterone) is an en-striatum and exerts other stimulant-like effects, for dogenous adrenal androgen available over-the-example increased alertness and motor activity, not counter in the US. It directly stimulates dopamine distinguished from cocaine. [25, 233] On the other hand, release in animals and circulating levels of praster-pretreatment with vanoxerine reduces cocaine selfone are lower than normal in chronic cocaine administration and cocaine-induced increases in users. [227] These findings led to a recent controlled brain extracellular dopamine levels. [25, 233] These clinical trial, which found that prasterone 100 mg/ findings suggest that vanoxerine might act either as day worsened treatment retention and increased co-a true cocaine antagonist (i.e. blocking cocaine's caine use compared with placebo. [231] access to the dopamine transporter) or as a stimulant The negative findings with ketoconazole, dexa-that substitutes for the effects of cocaine. In human methasone and prasterone suggest that manipulation phase I studies, vanoxerine was well tolerated, and of the HPA axis may not be a promising treatment produced sedation, rather than excitation. [234] A approach in humans. This seems contrary to the phase I cocaine-interaction study is currently underpromising results in animal studies (see section way; phase II clinical trials are under consideration 3.2.6), but there are important differences between (F. Vocci, personal communication). a Administration with cocaine to cocaine-using subjects to evaluate safety, influence on acute cocaine effects.
b Administration to healthy subjects to evaluate safety. NIDA = US National Institute on Drug Abuse.
NS 2359 is another inhibitor of the dopamine high hepatic first-pass metabolism, resulting in very low bioavailability (about 4%) after oral administratransporter that is undergoing a phase I human labotion. This obstacle may be circumvented by the ratory study evaluating the safety of single doses development of a formulation suitable for inhalation and their interaction with cocaine (A. Elkashef, per-(intrapulmonary delivery). BP 897 is a partial agosonal communication communication). Additional nist of D3 receptors. [51] It reduces cocaine self-addopamine transporter inhibitors that produce slowministration in rats (although not in monkeys), withonset, long-lasting blockade or that may block coout itself being self-administered (see section 3.1.2). caine binding without influencing dopamine reupHuman phase II trials are currently underway. [51] take [235] are in preclinical development. For example, (+)-CPCA is a piperidine-based cocaine ana-CEE 03310 is a selective D 1 receptor antagonist logue that is similar in binding to the dopamine and being developed for sleep disorders and substance norepinephrine transporters, but weaker in binding abuse. Phase I studies show that it is well toleratto the serotonin transporter.
[236] As might be expec-ed. [238] Phase II studies in substance abuse are schedted, it is self-administered by animals, but is a weak-uled to begin shortly in the US. Another D1 receptor er reinforcer than cocaine.
[236] Thus, it might be antagonist, ecopipam (SCH 39166), was found to useful in the stimulant substitution approach. It is increase cocaine self-administration and positive scheduled for human phase I safety trials. Methyl-subjective ratings of cocaine in a human experimenphenidate analogues are also in preclinical develop-tal study, [239] while not altering cocaine craving. [240] ment as substitution treatment. [26] It is no longer considered a promising candidate for development. Two selective dopamine receptor agonists are undergoing phase I and IIa trials. [87] Adrogolide is a Animal studies suggest that stimulation of opioid prodrug which is rapidly converted in plasma to κ receptors inhibits the firing of and release of A 86929, a D 1 receptor agonist. [43] In animal studies, dopamine from neurons of the dopamine reward it reduces cocaine self-administration and the ability system (see section 3.2.2), and reduces the reof a priming dose of cocaine to reinstate self-admin-warding effects of cocaine in several animal behavistration, without itself being self-administered (see ioural models, for example self-administration, consection 3.1.2). In a human laboratory study, adro-ditioned place preference and reinstatement. [241, 242] golide (2 or 4mg intravenously) was well tolerated Given these findings, opioid κ receptor agonists are by cocaine abusers and reduced some of the acute promising candidates for medication development psychological effects of smoked cocaine (12 or for the management of cocaine abuse. Existing ago50mg), while not reducing cocaine self-administra-nists, such as cyclazocine, are not useful because of dysphoric and psychotomimetic effects. A newer tion. [237] A practical drawback of adrogolide is its opioid κ agonist, enadoline, was well tolerated in
The blocking approach (so-called 'cocaine vacphase I and IIa clinical trials, but did not significant-cine') has been implemented in two ways.
[250] The ly reduce the acute psychological effects of cocaine cocaine molecule, itself too small to be antigenic, or cocaine self-administration in a laboratory study has been coupled to a large carrier protein. Alternaof cocaine users. [242] tively, an antibody molecule configured to mimic GV 196771 is an NMDA antagonist at the gly-the cocaine molecule can serve as the antigen (anticine binding site that is undergoing phase I evalua-idiotypic antibody). [251] Both types of antibodies can tion. [243] A controlled clinical trial (phase IIb) in significantly alter cocaine pharmacokinetics. The cocaine-dependent outpatients is planned.
only human studies to date have used succinylnorcocaine covalently linked to recombinant cholera toxin B subunit to make cocaine antigenic (cocaine abuse 6. Pharmacokinetic vaccine TA-CD). [252] In a randomised, double-blind, Treatment Approach placebo-controlled, phase I study, 34 healthy, abstinent cocaine abusers received up to three doses (13, There is growing interest in pharmacokinetic ap-82 or 709μg) of this vaccine (with aluminium hyproaches to the treatment of cocaine dependence, droxide adjuvant) over 8 weeks and were followed that is, to preventing cocaine from reaching its up for 1 year. [252] Two phase IIa trials have been site(s) of action in the brain. This could be accom-conducted. In the first trial, 19 cocaine abusers replished by preventing ingested cocaine from enter-ceived up to five doses (82 or 360μg) of this vaccine ing the brain (crossing the blood-brain barrier) or by over 12 weeks.
[253] In the second trial, 21 cocaine enhancing the elimination of cocaine from the body abusers received up to five doses (100 or 400μg) of so that less reached the site of action.
[244] The suc-this vaccine over 12 weeks, with some subjects cess of a pharmacokinetic treatment would depend receiving a booster dose at 15-18 months. [254] Findon its having sufficient activity to preclude ability of ings in all three studies were consistent. The active a patient to overcome the treatment by taking larger immunisation was well tolerated locally and systemamounts of cocaine.
ically. Serum levels of anti-cocaine antibody correThree pharmacokinetic techniques are being lated with both vaccine dose and number of vaccinastudied: (i) binding with anti-cocaine antibodies that tions. Detectable antibody levels appeared after the form complexes too large to cross the blood-brain second vaccination, peaked 8-12 weeks later and barrier (blocking approach); (ii) increasing cocaine remained for up to 9 months. Subjects who used catabolism with enzymes; or (iii) increasing cocaine cocaine during the phase IIa studies anecdotally catabolism with catalytic antibodies (catalytic ap-reported attenuation of the expected euphoric effects proach). All three techniques, when used as pretreat-of cocaine. [253, 254] There was a rough negative assoment before cocaine administration, have been suc-ciation between vaccine dose or peak antibody level cessful in animal studies in reducing brain cocaine and degree of cocaine use, that is, the higher the concentrations and the behavioural effects of co-dose or antibody level, the less cocaine use (assessed caine. [245] [246] [247] The enzyme technique has been imple-by urine toxicology). A phase II efficacy study in mented preclinically with both the naturally occur-cocaine-abusing patients on methadone maintenring enzyme butyrylcholinesterase, a major cocaine ance treatment should begin in the near future metabolising enzyme in primates, or with recombi-(F. Vocci, personal communication). nant versions of the human enzyme which have At least two other companies have anti-cocaine enhanced catalytic properties. [248] Other naturally antibodies in preclinical development: [255] one a occurring enzymes that catabolise cocaine, such as blocking antibody (ITAC-cocaine; Drug Abuse Scibacterial cocaine esterase, are also being considences, CA, USA) induced by active immunisation ered. [249] There have not yet been any human studies with either enzyme or catalytic antibody.
(analogous to cocaine abuse vaccine TA-CD); and another a monoclonal catalytic antibody (15A10;
Conclusion
Vocci of the US NlDA for information about the institute's medication development programmes. Dr Gardner has received past research grant funding from GlaxoSmithKline
Cocaine dependence is a significant public health Pharmaceuticals for anti-cocaine addiction pharmacotherproblem in many countries of the world, yet there is apeutic drug discovery and development. no effective medication approved for its treatment.
